

Marco Galasso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8452369/publications.pdf>

Version: 2024-02-01

33
papers

2,125
citations

304602

22
h-index

395590

33
g-index

34
all docs

34
docs citations

34
times ranked

4369
citing authors

#	ARTICLE	IF	CITATIONS
1	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. <i>Frontiers in Endocrinology</i> , 2022, 13, 834075.	1.5	5
2	UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. <i>Genes</i> , 2021, 12, 1978.	1.0	5
3	The network of non-coding RNAs and their molecular targets in breast cancer. <i>Molecular Cancer</i> , 2020, 19, 61.	7.9	36
4	miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. <i>Progress in Neurobiology</i> , 2020, 190, 101803.	2.8	31
5	MiR-161-3p and miR-162-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma. <i>International Journal of Cancer</i> , 2019, 145, 3052-3063.	2.3	27
6	An Ultraconserved Element Containing lncRNA Preserves Transcriptional Dynamics and Maintains ESC Self-Renewal. <i>Stem Cell Reports</i> , 2018, 10, 1102-1114.	2.3	17
7	A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants. <i>Amino Acids</i> , 2018, 50, 421-438.	1.2	7
8	Loss of miR-204 expression is a key event in melanoma. <i>Molecular Cancer</i> , 2018, 17, 71.	7.9	25
9	Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts. <i>Biomarker Research</i> , 2018, 6, 31.	2.8	17
10	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 334-346.	2.3	43
11	Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. <i>Frontiers in Genetics</i> , 2018, 9, 174.	1.1	46
12	Levels of miR-126 and miR-218 are elevated in ductal carcinoma <i>in situ</i> (DCIS) and inhibit malignant potential of DCIS derived cells. <i>Oncotarget</i> , 2018, 9, 23543-23553.	0.8	12
13	Blood to skin recirculation of CD4 + memory T cells associates with cutaneous and systemic manifestations of psoriatic disease. <i>Clinical Immunology</i> , 2017, 180, 84-94.	1.4	26
14	miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. <i>Cancer Cytopathology</i> , 2017, 125, 635-643.	1.4	18
15	Risk factors associated with relapse of eyelid basal cell carcinoma: results from a retrospective study of 142 patients. <i>European Journal of Dermatology</i> , 2017, 27, 363-368.	0.3	5
16	Profiling of the Predicted Circular RNAs in Ductal In Situ and Invasive Breast Cancer: A Pilot Study. <i>International Journal of Genomics</i> , 2016, 2016, 1-7.	0.8	30
17	miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. <i>Oncotarget</i> , 2015, 6, 4920-4935.	0.8	58
18	A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas. <i>PLoS ONE</i> , 2014, 9, e108950.	1.1	60

#	ARTICLE	IF	CITATIONS
19	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. <i>Oncotarget</i> , 2014, 5, 7162-7171.	0.8	35
20	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. <i>Genome Medicine</i> , 2014, 6, 76.	3.6	32
21	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	37
22	Next generation analysis of breast cancer genomes for precision medicine. <i>Cancer Letters</i> , 2013, 339, 1-7.	3.2	19
23	Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status. <i>PLoS Genetics</i> , 2013, 9, e1003311.	1.5	139
24	Association between idiopathic hearing loss and mitochondrial DNA mutations: A study on 169 hearing-impaired subjects. <i>International Journal of Molecular Medicine</i> , 2013, 32, 785-794.	1.8	16
25	MicroRNA Expression Signatures in Solid Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 238-243.	1.0	72
26	Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3024-3029.	3.3	334
27	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E μ -miR-155 transgenic mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20047-20052.	3.3	121
28	miRNA Signatures Associate with Pathogenesis and Progression of Osteosarcoma. <i>Cancer Research</i> , 2012, 72, 1865-1877.	0.4	341
29	Prion proteins (PRNP and PRND) are overexpressed in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2012, 30, 1004-1012.	1.2	15
30	GAMES identifies and annotates mutations in next-generation sequencing projects. <i>Bioinformatics</i> , 2011, 27, 9-13.	1.8	28
31	Reprogramming of miRNA networks in cancer and leukemia. <i>Genome Research</i> , 2010, 20, 589-599.	2.4	331
32	Identification of microRNA activity by Targets' Reverse EXpression. <i>Bioinformatics</i> , 2010, 26, 91-97.	1.8	39
33	Non-coding RNAs: a key to future personalized molecular therapy?. <i>Genome Medicine</i> , 2010, 2, 12.	3.6	97